Dayvigo Dosage/Direction for Use

The usual dosage for adults is 5 mg of lemborexant administered orally once daily immediately before bedtime.
Precautions regarding dosage and administration: 1. Instruct the patient to take DAYVIGO immediately before bedtime. Instruct the patient not to take DAYVIGO if there is any possibility of waking up temporarily in the middle of sleep to engage in activities, such as to work, after taking this product and going to sleep.
2. Since sleep induction may be delayed, avoid taking DAYVIGO at the same time or right after meals. (With postprandial administration, the plasma lemborexant concentration immediately after the administration may decrease compared to that with administration on an empty stomach.) (See Pharmacology: PHARMACOKINETICS under Actions.)
3. Concomitant use of DAYVIGO with strong or moderate CYP3A inhibitors is contraindicated. Concomitant use of DAYVIGO with strong or moderate CYP3A inducers is contraindicated. The recommended dosage of DAYVIGO is 5 mg no more than once per night when co-administered with weak CYP3A inhibitors. (See Pharmacology: PHARMACOKINETICS under Actions.)
4. Since plasma lemborexant concentration increase in patients with moderate hepatic function disorder, the dosage may not exceed 5 mg once daily in these patients, and should be administered with care. (See Careful Administration under Precautions and Pharmacology: PHARMACOKINETICS under Actions.)
5. The efficacy and safety of concomitant use with other drugs for treatment of insomnia have not been established.
6. Patients should be advised not to consume alcohol in combination with DAYVIGO.
7. When DAYVIGO is combined with other central nervous system (CNS) depressant drugs, dosage adjustment of DAYVIGO and/or the other drug(s) may be necessary because of potentially additive effects.